Disease landscape

Pancreatic Cancer clinical trials

Get alerts when Pancreatic Cancer trials change

1,218 active trials 692 recruiting 77 Phase 3 617 sponsors 150 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 47 of 150 changes on 20 trials

2026-08-29
Withdrawn before enrolling
Trial withdrawn: The sponsor has changed the development plans which is not for safety reasons.
NCT07488884 Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept… · ImmunityBio, Inc. · Phase 1
2026-09-03
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: Study was stopped Sponsor discretion. No patients were dosed.
NCT06487377 IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… · Shanghai Pudong Hospital · Phase 1
2026-09-02
Trial terminated
Trial terminated: In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has...
Final enrollment: 1 participants — 6% of the 18 planned
Primary completion confirmed: June 2026 (last estimated June 2028)
NCT05438667 TCR-T Cell Therapy on Advanced Solid Tumors · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Early Phase 1
2026-09-05
Primary completion pushed: 2027-02 → 2029-06
Primary endpoint(s) modified
Enrollment increased: 495 → 575 participants
Interventions modified
Completion pushed: 2027-04 → 2029-06
Trial arms changed: 9 → 11
NCT06400472 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · Eli Lilly and Company · Phase 1
2026-09-02
Primary completion pushed: 2026-01-28 → 2026-10-01
NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid… · Taiho Oncology, Inc. · Phase 2
2026-09-04
Primary completion pushed: 2026-04 → 2026-12
Enrollment closed, study ongoing
Completion pushed: 2026-04 → 2026-12
NCT06337084 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · Monopar Therapeutics · Phase 1
2026-08-25
Primary completion pushed: 2026-06 → 2027-06
Completion pushed: 2026-09 → 2027-09
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy… · RenovoRx · Phase 3
2026-09-05
Primary completion pushed: 2030-12-31 → 2034-11-11
Completion pushed: 2031-12-31 → 2034-11-11
NCT04239573 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated… · ECOG-ACRIN Cancer Research Group
2026-08-27
Primary completion pushed: 2026-06 → 2026-12
NCT04157127 Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma · Diakonos Oncology Corporation · Phase 1
2026-08-14
Primary completion pushed: 2026-03 → 2027-03
Completion pushed: 2026-03 → 2027-03
NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. · Phase 1/2
2026-08-12
Primary completion pushed: 2025-06-30 → 2026-12-30
Sponsor changed: Evopoint Biosciences Inc. → Astellas Pharma Global Development, Inc.
Enrollment closed, study ongoing
Completion pushed: 2025-12-31 → 2027-06-30
NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. · Astellas Pharma Global Development, Inc. · Phase 1/2
2026-09-05
Primary completion pushed: 2026-06-01 → 2027-06-01
NCT04005690 Targeted Pathway Inhibition in Patients With Pancreatic Cancer · OHSU Knight Cancer Institute · Early Phase 1
2026-08-20
Primary completion pushed: 2026-05-30 → 2026-08-30
NCT05919238 Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma · Impact Biotech Ltd · Phase 1
2026-09-03
Primary completion pushed: 2026-04-01 → 2027-08-01
Completion pushed: 2027-04-01 → 2027-08-01
NCT04611867 Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay) · Inna Chen, MD
2026-09-03
Primary completion pushed: 2026-07-24 → 2027-07-24
Completion pushed: 2026-07-24 → 2027-07-24
NCT05837767 A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue · Memorial Sloan Kettering Cancer Center
2026-08-28
Primary completion pushed: 2031-01-01 → 2033-04-01
Recruitment opened
Completion pushed: 2031-09-01 → 2034-09-01
NCT05314998 Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or… · John Neoptolemos · Phase 3
2026-09-02
Primary completion pushed: 2027-03 → 2027-12
Completion pushed: 2027-09 → 2027-12
NCT05526443 Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With… · Medical University of Graz
2026-08-22
Primary completion pushed: 2026-08-26 → 2028-08-26
Completion pushed: 2026-08-26 → 2028-08-26
NCT05554367 Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · National Cancer Institute (NCI) · Phase 2
2026-09-01
Primary completion pushed: 2026-06 → 2027-06
Completion pushed: 2026-06 → 2027-06
NCT05497531 Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and… · University of California, Irvine
2026-09-03
Primary endpoint(s) modified
Trial completed
Primary completion confirmed: June 2026 (last estimated June 2027)
NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in… · Sensei Biotherapeutics, Inc. · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-04 NCT07803783 A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in… MediLink Therapeutics (Suzhou) Co., Ltd. new Phase 3
2026-09-04 NCT07805681 Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test… Immunovia, Inc. new
2026-08-26 NCT07787156 Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial Brigham and Women's Hospital new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-20 NCT07777211 A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer Beijing Gene Key Life Technology Co., Ltd new Phase 1/2
2026-08-20 NCT07776353 Understanding New Cachexia Subtypes Through Observational Epidemiological Research Kaiser Permanente new
2026-08-19 NCT07772258 Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for… Manchester University NHS Foundation Trust new
2026-08-19 NCT07773363 Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic… Tang-Du Hospital new Phase 2
2026-08-13 NCT07763561 EUS-DFI in Solid Pancreatic Lesions Julio Iglesias García new
2026-08-10 NCT07756281 First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic… Synnovation Therapeutics, Inc. new Phase 1

Active trials by phase

Early Phase 1
38
Phase 1
188
Phase 1/2
173
Phase 2
266
Phase 2/3
23
Phase 3
54
Phase 4
12
Not charted: 464 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 1,218

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07262957 Preventing Postoperative Complications in Patients Undergoing High-risk… Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting 2025-12-22
NCT06099119 Efficacy of PERT for PEI in Unresectable Pancreatic Cancer. Hospital Clinico Universitario de Santiago Recruiting 2025-06-06
NCT05784311 Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) Leiden University Medical Center Recruiting 2024-10-21
NCT06368063 The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic… Xi'an Jiaotong University Recruiting 2024-05-08
NCT05035147 Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer Tianjin Medical University Cancer Institute and Hospital Recruiting 2021-09-21
NCT07557394 A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui… Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not Yet Recruiting 2026-04-29
NCT05634720 Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer Duke University Active, Not Recruiting 2026-01-26
NCT07302841 Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer Tianjin Medical University Cancer Institute and Hospital Not Yet Recruiting 2025-12-24
NCT04025840 Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Peking University First Hospital Active, Not Recruiting 2025-07-31
NCT06779318 Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected… The First Affiliated Hospital with Nanjing Medical University Not Yet Recruiting 2025-04-03
NCT06387368 Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Xi'an Jiaotong University Not Yet Recruiting 2024-04-29
NCT02775227 HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications Helsinki University Central Hospital Active, Not Recruiting 2020-08-24
Phase 3
NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic… Immuneering Corporation Recruiting 2026-09-04
NCT05314998 Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or… John Neoptolemos Recruiting 2026-08-27
NCT07409272 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… Astellas Pharma Global Development, Inc. Recruiting 2026-08-27
NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… Revolution Medicines, Inc. Recruiting 2026-08-27
NCT06958328 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NRG Oncology Recruiting 2026-08-25
NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… Revolution Medicines, Inc. Recruiting 2026-08-25
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy… RenovoRx Recruiting 2026-08-24
NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… Revolution Medicines, Inc. Recruiting 2026-08-21
NCT07262567 Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant… Genfleet Therapeutics (Shanghai) Inc. Recruiting 2026-08-14
NCT07232875 HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line… Jiangsu HengRui Medicine Co., Ltd. Recruiting 2026-07-15
NCT07436741 Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in… Tianjin Medical University Cancer Institute and Hospital Recruiting 2026-07-10
NCT07217717 Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal… SOFIE Recruiting 2026-06-30
NCT07632118 Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following… Tianjin Medical University Cancer Institute and Hospital Recruiting 2026-06-08
See all 1,218 active Pancreatic Cancer trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (30) · Fudan University (26) · M.D. Anderson Cancer Center (21) · Memorial Sloan Kettering Cancer Center (21) · Ruijin Hospital (19) · Mayo Clinic (15) · Changhai Hospital (14) · Tianjin Medical University Cancer Institute and Hospital (14) · Zhejiang University (14) · City of Hope Medical Center (12)

Get alerts when Pancreatic Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free